Clinical trial

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

NCT02695290

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2016-03-17

PhasePHASE4

Study timeline

Study start (actual)2016-03-17Date precision: day

Registry last updated2017-09-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

ErbB Receptorsunresolved

Interventions

AfatinibDRUG · verified · RxNorm: afatinib

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

Fountain ValleyCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02695290 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.